These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26197752)

  • 21. Zoledronic acid in metastatic bone disease: an audit based discussion.
    Akbar RA; Gosh SK; Khalil S; ul Haq SM
    J Ayub Med Coll Abbottabad; 2010; 22(3):5-7. PubMed ID: 22338405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer.
    Kishimoto Y; Iwase T; Koyama A; Masui T; Yoshida G; Matsuo H; Ishiguro N
    Nagoya J Med Sci; 2011 Aug; 73(3-4):211-5. PubMed ID: 21928703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
    Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
    Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
    Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
    J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer.
    Goldman ML; Denduluri N; Berman AW; Sausville R; Guadagnini JP; Kleiner DE; Brahim JS; Swain SM
    Oncology; 2006; 71(3-4):306-8. PubMed ID: 17657174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid.
    Ishizuna K; Ota D; Fukuuchi A; Teraoka M; Fujii A; Mori M; Nishi T
    Breast Cancer; 2015 Jan; 22(1):90-4. PubMed ID: 22009549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
    J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
    Hanamura M; Iwamoto T; Soga N; Sugimura Y; Okuda M
    Biol Pharm Bull; 2010; 33(4):721-4. PubMed ID: 20410614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
    Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
    J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
    [No Abstract]   [Full Text] [Related]  

  • 32. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
    Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.
    Ishii S; Kikuchi K; Miyajima M; Sakuma K; Shishido F
    Fukushima J Med Sci; 2015; 61(1):23-31. PubMed ID: 25946906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
    Body JJ; Gatta F; De Cock E; Tao S; Kritikou P; Wimberger P; Mebis J; Peeters M; Pedrazzoli P; Caraceni A; Adamo V; Hechmati G
    Support Care Cancer; 2017 Sep; 25(9):2823-2832. PubMed ID: 28429148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
    Cure E; Yuce S; Cure MC
    Minerva Endocrinol; 2013 Jun; 38(2):217-8. PubMed ID: 23732377
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A successful case treated with S-1 and zoledronic acid for multiple bone metastasis of breast cancer].
    Nakamoto Y; Kayata Y; Kikawa Y; Ogata M; Yamamoto M
    Gan To Kagaku Ryoho; 2011 May; 38(5):811-3. PubMed ID: 21566443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
    Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.
    Mücke T; Deppe H; Hein J; Wolff KD; Mitchell DA; Kesting MR; Retz M; Gschwend JE; Thalgott M
    J Craniomaxillofac Surg; 2016 Oct; 44(10):1689-1693. PubMed ID: 27555374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.